Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9279659 | 0.91 | RAB9A (0.41) | PTPN1LMNAHPGDTHRATHRB | |
| SCHEMBL20370165 | 0.90 | PTPN1 (0.42) | PTPN1LMNAHPGDMAOBRAB9A | |
| SCHEMBL114746 | 0.90 | PTPN1 (0.42) | PTPN1LMNAHPGDMAOBRAB9A | |
| SCHEMBL9285946 | 0.89 | PTPN1 (0.40) | PTPN1LMNAHPGDTHRATHRB | |
| SCHEMBL9279189 | 0.89 | PTPN1 (0.38) | PTPN1LMNAHPGDTHRATHRB | |
| SCHEMBL12108777 | 0.87 | PTPN1 (0.40) | PTPN1LMNAHPGDTHRATHRB | |
| SCHEMBL9284201 | 0.87 | PTPN1 (0.40) | PTPN1LMNAHPGDTHRATHRB | |
| SCHEMBL9287110 | 0.87 | EGFR (0.39) | PTPN1LMNAHPGDTHRATHRB | |
| SCHEMBL12108764 | 0.86 | PTPN1 (0.38) | PTPN1LMNAHPGDTHRATHRB | |
| SCHEMBL6128441 | 0.86 | FAAH (0.38) | LMNATHRATHRBNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| EP-2424834-B1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THEREOF | HARVARD COLLEGE (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2424834-B1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THEREOF | HARVARD COLLEGE (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9688644-B2 | Synthesis of Tetracyclines and intermediates thereto | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688644-B2 | Synthesis of Tetracyclines and intermediates thereto | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688644-B2 | Synthesis of Tetracyclines and intermediates thereto | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170107179-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2017-04-20 | — | — | US | disclosed |
| US-20170107179-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2017-04-20 | — | — | US | disclosed |
| EP-2427425-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20160002183-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002183-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-07 | — | — | US | disclosed |
| US-9073829-B2 | Synthesis of tetracyclines and intermediates thereto | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073829-B2 | Synthesis of tetracyclines and intermediates thereto | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-07 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2424834-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | President and Fellows of Harvard College (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2010126607-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | TET1, TET3, TYMS | PTPN1 2298/4885LMNA 1424/4885HPGD 1380/4885 |
| US-20160002183-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | TECR, TAOK1, TET1 | PTPN1 1626/4885LMNA 1452/4885HPGD 1526/4885 |
| US-20170107179-A1 | Polycyclic Tetracycline Compounds | TET1, TUBA1C, TUBB | PTPN1 470/4885LMNA 2586/4885HPGD 3299/4885 |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | PTPN1 402/4885LMNA 3089/4885HPGD 2557/4885 |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TET1, TUBA1C, TUBB | PTPN1 470/4885LMNA 2586/4885HPGD 3299/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | PTPN1 402/4885LMNA 3089/4885HPGD 2557/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | PTPN1 402/4885LMNA 3089/4885HPGD 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.